Is a complete KZIA research report available?

No complete published report is available for Kazia Therapeutics Limited (KZIA) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Kazia Therapeutics Limited (KZIA)

NASDAQ: KZIA · USD

$12.8

+0.79 (+6.6%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first KZIA analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	146.5M
Revenue (ttm)	1.3M
Net income (ttm)	-15.2M
EPS (ttm)	-$6.82
Shares out	11.4M
Volume	329,562
Beta	2.15
Price target	$27.5	+114.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.3M
Net income (ttm): -15.2M
EPS (ttm): -$6.82
Market cap: 146.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All KZIA indicators

Market & fundamental data

Available fields

204

Groups with data

Currency

AUD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001055886
Company name	Kazia Therapeutics Limited
Country	Australia
Country code	US
Cusip	48669G303
Employees	6
Employees Change	-0.8%
Employees Change Percent	-11.76
Enterprise value	$100.2M
Exchange	NASDAQ
Financial currency	AUD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1999-01-06
Isin	US48669G3039
Last refreshed	2026-07-31
Market cap	$146.5M
Market cap category	Micro-Cap
Price	$12.82
Price currency	USD
Rev Per Employee	211,071.5x
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	8880
Symbol	KZIA
Website	https://www.kaziatherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-10.38%
EV Sales Forward	963.72x
EV/Sales	79.14x
FCF yield	-6.91%
P/B ratio	4.4x
P/S ratio	115.67x
PS Forward	1,408.59x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$1.3M
Gross Profit Growth	-24.15%
Gross Profit Growth Q	1,838,320%
Gross Profit Growth5 Y	39.18%
Net Income	$-15.2M
Net Income Growth Years	1%
Pretax Margin	-1,285.72%
Profit Per Employee	$-2.5M
ROA	-25.7
Roa5y	-45.34
ROCE	-65.12
ROE	-106.9
ROIC	-53.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-28.6%
Cagr15y	-19.18%
Cagr1y	48.76%
Cagr20y	-24.59%
Cagr3y	-35.59%
Cagr5y	-50.99%
EPS Growth Years	3
Revenue Growth	-24.15x
Revenue Growth Q	312.39x
Revenue Growth Years	0x
Revenue Growth5 Y	39.18x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.04
Assets	$47.4M
Cash	$46.3M
Current Assets	$49.2M
Current Liabilities	$17.1M
Debt	$65,906
Debt Equity	$0
Equity	$31M
Liabilities	$16.4M
Long Term Assets	$-1.8M
Long Term Liabilities	$-699,956
Net Cash	$46.3M
Net Cash By Market Cap	$31.58
Net Cash Growth	2,065.3%
Net Debt Equity	$-1.49
Tangible Book Value	$30.3M
Tangible Book Value Per Share	$2.67
WACC	16.08

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.87
Net Working Capital	$-15.8M
Quick ratio	2.86
Working Capital	$30.4M
Working Capital Turnover	$0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-213.01%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-96.55%
1Y total return	48.72%
200-day SMA	9.73
3Y total return	-73.29%
50-day SMA	13.06
50-day SMA vs 200-day SMA	50over200
5Y total return	-97.17%
All Time High	31,900
All Time High Change	-99.96%
All Time High Date	2003-12-08
All Time Low	2.86
All Time Low Change	348.25%
All Time Low Date	2025-04-17
ATR	1.12
Beta	2.15
Beta1y	2.98
Beta2y	1.59
Ch YTD	86.07
High	13
High52	17.4
High52 Date	2025-12-08
High52ch	-26.32%
Low	11.93
Low52	4.86
Low52 Date	2026-02-12
Low52ch	163.79%
Ma50ch	-1.82%
Price vs 200-day SMA	31.72%
RSI	47.7
RSI Monthly	41.42
RSI Weekly	55.91
Sharpe ratio	0.87x
Sortino ratio	1.54
Total Return	-213.01%
Tr YTD	86.07
Tr15y	-95.9%
Tr1m	-11.34%
Tr1w	-1.69%
Tr3m	3.22%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	1
Analyst Price Target Top	$34
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Operating Income	$-12.2M
Operating margin	-964.2
Price target	$27.5
Price Target Change	$115
Price Target Change Top	$165

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8,103,787%
Float Percent	70.92%
Shares Insiders	18.61%
Shares Institutions	16.82%
Shares Out	11,426,899
Shares Qo Q	132.62%
Shares Yo Y	213.01%
Short Ratio	4.34
Short Shares	6.49

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-13.5M
Adjusted OCF	-13,516,483.8
Average Volume	193,643.95x
Bv Per Share	2.73
Ch10y	-96.55
Ch15y	-98.65
Ch1m	-11.34
Ch1w	-1.69
Ch1y	48.72
Ch20y	-99.88
Ch3m	3.22
Ch3y	-73.29
Ch5y	-97.17
Ch6m	110.2
Change	6.57%
Change From Open	4.48
Close	12.03
Days Gap	2
Depreciation Amortization	327,889.2
Dollar Volume	4,224,984.8
Earnings Date	2026-03-30
Earnings Time	bmo
EBIT	$-20.3M
EBITDA	$-13.7M
EPS	$-6.82
F Score	2
FCF	$-10.1M
FCF EV Yield	-10.1x
FCF Per Share	$-0.89
Financing CF	54,404,826
Fiscal Year End	June
Founded	1,994
Income Tax	$-1.1M
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-30
Last Report Date	2025-12-31
Last Split Date	2025-04-17
Last Split Type	Reverse
Ma150	10
Ma150ch	28.23%
Ma20	13.14
Ma20ch	-2.41%
Net CF	44,287,926
Next Earnings Date	2026-11-06
Open	12.27
Optionable	Yes
Position In Range	83.18
Post Close	12.82
Postmarket Change Percent	0.55
Postmarket Price	$12.89
Price Date	2026-07-30
Ptbv Ratio	4.84
Relative Volume	1.7x
Revenue	1,266,429x
SBC By Revenue	254.04x
Share Based Comp	3,217,261
Tax By Revenue	-84.82x
Tr20y	-99.65%
Tr6m	110.16%
Volume	329,562
Z Score	-2.53

Kazia Therapeutics Limited (KZIA)

Coverage state: Market snapshot only — no published research

Generate the first KZIA analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · KZIA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KZIA indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on KZIA

Frequently asked questions